

## High-throughput fluorescent assay for inhibitor screening of proteases from RNA viruses

Bara Cihlova, Andrea Huskova, Jiri Böserle, Radim Nencka, Evzen Boura\*, Jan Silhan\*

Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences

\* To whom correspondence should be addressed: [silhan@uochb.cas.cz](mailto:silhan@uochb.cas.cz);  
[boura@uochb.cas.cz](mailto:boura@uochb.cas.cz)

### Abstract

Spanish flu and other influenza outbreaks, the recent Zika epidemics, and the ongoing COVID-19 pandemic are the most profound examples of severe widespread diseases that are caused by RNA viruses. Perhaps less well known yet dangerous RNA viruses cause deadly diseases such as polio, Ebola, measles, rubella, yellow fever, dengue fever and many others. To combat a particular viral disease by diminishing its spread and number of fatal cases, effective vaccines and antivirals are indispensable. Therefore, quick access to the means of discovery of new treatments for any epidemic outbreak is of great interest and *in vitro* biochemical assays are the basis of drug discovery. The recent outbreak of the coronavirus pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) demands an affordable and reliable assay for testing antivirals. Here, we developed a quick and inexpensive high-throughput fluorescent assay to test inhibitors of viral proteases. Accordingly, we employed this assay to sample inhibitors for papain-like protease from SARS-CoV-2. In addition, we validated this assay for screening inhibitors of flaviviral protease from the tick-borne encephalitis virus to emphasize a broad range of applications of our approach. This fluorescent high-throughput assay is based on fluorescent energy transfer (FRET) between two distinct fluorescent proteins (eGFP and mCherry) connected via a substrate polypeptide. When the substrate is cleaved, FRET is abolished and the change in fluorescence corresponds to reaction progress. Our data show that this assay can be used for testing the inhibitors in the 96 or 384 well plates format with robust and reproducible outcomes.

**Keywords:** high-throughput screening, virus, drug, discovery, protease, SARS-CoV-2, Flavivirus

## Introduction

RNA viruses are considered to be one of the most severe threats to the human population and quality of life [1]. Since the beginning of this millennium, we have witnessed at least 60 epidemic outbreaks around the world, mostly caused by RNA viruses. Excluding the ongoing COVID-19 pandemic, these have caused more than a million deaths. The viruses responsible include: influenza virus, Ebola virus (EBOV), Zika virus (ZIKV), yellow fever virus (YFV), dengue viruses (DENV), measles, and coronaviruses such as SARS, MERS, and SARS-CoV-2. The effect on human health is devastating, just as is the economic burden of these epidemics. The global cost of COVID-19 alone is astronomical and is predicted to surpass the GDPs of Germany, the UK and France combined. Therefore, the global importance of targeting the RNA viruses is indisputable.

The name and classification of RNA viruses originate from their genomic material which is composed of single-stranded or double-stranded RNA. Recent work has classified RNA viruses into 5 different orders with 47 families [2]. Although the nature of nucleic acid determines the classification of these viruses, more detailed classification is difficult due to the high mutation rate and recombination of the RNA viruses [3, 4]. RNA viruses have the highest mutation rates among all viruses, which often leads to the development of resistance against antivirals. These high mutation rates generate new species, where 2-3 novel viruses are discovered every year [5]. Understanding how mutation rates drive and shape the evolution of new and potentially deadly viruses that can cross interspecies boundaries is an ongoing topic of scientific interest [6].

Upon the infection of the host cell, viral RNA is replicated by viral RNA-dependent RNA polymerase and translated to one or more polyproteins. Subsequently, these polyproteins are processed by viral and host proteases into individual structural and nonstructural proteins. The presence and the functionality of viral enzymes, particularly proteases and polymerases, is a vital step in the replication and spread of the virus. A potential antiviral drug is correspondingly aimed at inhibiting the viral enzymes, thus limiting the spread of the virus. However, approved antivirals against RNA viruses are generally lacking, and only a few RNA viruses can be currently treated by approved antivirals: the influenza virus, the respiratory syncytial virus, and hemorrhagic viruses such as the Lassa mammarenavirus or the hepatitis C virus (HCV). Without antiviral drugs, the only current form of treatment is supportive care, i.e. relieving pain and other symptoms. What has been raising hope for developing RNA antivirals are the successes of antiviral therapy against the HCV [7]. The potent effects of these antivirals are mainly based on targeting proteases and polymerases, two of the essential viral enzymes. Basic research of these enzymes has formed the groundwork of rational drug design, enabling the development of specific molecules that bind and inhibit the enzymes. However, the action of novel synthetic molecules within the human body is rather unpredictable, leading to a high failure rate in the later stages of clinical trials. Additionally, the rapid rates of mutation further increase the overall fitness of the virus, making it

resistant to antiviral agents, especially in the case of single-compound regimens. Greater antiviral effect is achieved by the combination of several antivirals, which usually include both polymerase and protease inhibitors.

A papain-like protease (PL<sup>pro</sup>) is one of two proteases encoded by the coronavirus SARS-CoV-2, the cause of the current COVID-19 pandemic. PL<sup>pro</sup> is a deubiquitinating-like (DUB-like) enzyme which negates the host interferon-induced cellular response by cleaving the interferon-stimulated gene 15 (ISG15). ISG15 is a small di-ubiquitin-like protein which is overexpressed during viral infection and covalently attached to newly synthesized proteins to mark the viral invader. ISG15 impedes the processes of the viral replication cycle. It is thought to block the formation of new viral particles due to the steric hindrance of ISG15 molecules attached to structural proteins that form the virion [8, 9]. Therefore, cessation of the viral defense mediated by PL<sup>pro</sup> makes it a *bona fide* therapeutic target. Moreover, the inhibition of the PL<sup>pro</sup> enzyme from other coronaviruses has been demonstrated to suppress viral replication [10-12].

Tick-borne encephalitis (TBE) is the most significant flaviviral tick-borne disease that causes brain damage, paralysis and death. There are 10,000 to 12,000 reported cases of TBE each year and an increase in the worldwide risk of incidence is predicted on account of the expansion of the tick population in times of global warming and human mobility [13-15]. Other severe human pathogens in the Flavivirus genus include ZIKV, DENV, YFV, West Nile virus (WNV) and Japanese encephalitis virus (JEV). The virology and enzymology of YFV, DENV, WNV and ZIKV have been studied extensively for the past 30 years, and several kinetic and structural studies of key enzymes are available [16-21]. Significant structural and functional similarity between proteins of a single genus make these findings transferable and instrumental in other studies [22].

TBEV polyprotein is processed into three structural proteins which form the envelope, membrane and capsid, and seven nonstructural (NS) proteins, named NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5. NS3 possesses two distinct activities, helicase and protease activity, on N-terminus and C-terminus, respectively. NS3 protease (NS3<sup>pro</sup>) is a chymotrypsin-like serine protease whose cleavage site is specified by the sequence XX↓Y where X is a positively charged residue and Y is a small residue such as serine or glycine [23]. NS2B anchors the NS3 to the endoplasmic reticulum by its termini, and is known to participate in the protease reaction.

Here, we report a general FRET-based method for high-throughput quantitative screening (HTS) of potential inhibitors, and for testing other enzymatic properties of viral and non-viral proteases. In addition to validating potential rationally designed molecules, HTS enables screening of already developed and clinically approved molecules that can potentially serve other purposes. As HTS plays

an indispensable role in antiviral drug development, the methods must be as economical and rapid as possible while granting high reproducibility and robustness.

For our assay, we have selected common, attainable and stable fluorescent proteins. The FRET pair of our choice consisted of a fluorescence donor (eGFP) and a fluorescence acceptor (mCherry). FRET is a non-radiative transfer of energy from one fluorophore (donor) to the other chromophore (acceptor). Essentially, FRET-based assays report on the distance between the donor and the acceptor. While the fluorophores are in close proximity, the donor is excited and transfers its energy to the acceptor, which then produces a fluorescence signal at its characteristic wavelength. Upon separation, i.e. increase in the distance between the fluorophores, FRET is abolished, and the acceptor ceases to produce the signal (Figure 1). Thanks to its dependence on inverse-sixth-power distance, FRET is a remarkably sensitive tool for measuring dissociation of molecules. FRET is also influenced by an overlap between the emission spectrum of the donor and absorption spectrum of the acceptor, quantum yield of the donor, orientation between fluorophores dipoles and other physical factors of the environment [24]. The fluorescent pair can be readily changed accordingly to the needs of a particular experiment. As a proof of principle, we have selected two medicinally significant targets, the PL<sup>pro</sup> from SARS-CoV-2 and the NS2B-NS3 protease from TBEV, and tested several small molecules to optimize and validate the assay for an array of molecules and also different classes of proteases.

## Materials and Methods

### Cloning, expression and purification of the recombinant NS2B-NS3<sup>pro</sup> and PL<sup>pro</sup>

The DNA sequence encoding the TBEV NS2B-NS3<sup>pro</sup> enzyme (strain Hypr; GeneBank: KP716978.1) was commercially synthesized (Invitrogen) and encoded NS2B (residues 45-96), a GGGGSGGGG linker and NS3 (residues 116-131) followed by a 6xHis-tag. The NS2B-NS3<sup>pro</sup> encoding gene was cloned into the NcoI and the NotI sites of pRSFD vector (Novagen). The vector was transformed into *Escherichia coli* (*E. coli*) NiCo21 (DE3) cells and cultured in LB medium with 40 µg/ml of kanamycin. The culture was left to shake overnight at 37 °C and then used to inoculate ZY5052 autoinduction media. After reaching an optical density of 0.6-0.8 (OD<sub>600</sub>) at 37 °C, the temperature was lowered to 18 °C and the culture was grown overnight. The cells were lysed by sonication in a lysis buffer containing 20 mM Tris-HCl pH = 8; 300 mM NaCl; 20mM imidazole; 10% glycerol and 3 mM β-mercaptoethanol (β-ME). The supernatant was separated by centrifugation, incubated with 2 ml of Ni-NTA resin (Machery-Nagel) and extensively washed with the lysis buffer using the batch technique. The slurry was loaded on the column and the protein was eluted with the lysis buffer supplemented with 300 mM imidazole pH = 8.0. The eluate was further purified using the size-exclusion Superdex 75 HiLoad 16/600 column (GE Healthcare) with a gel filtration buffer (20 mM Tris-HCl pH = 8; 300 mM

NaCl; 10% glycerol and 3 mM  $\beta$ -ME). Protein was desalted on a HiPrep 26/10 desalting column (GE Healthcare) and loaded on an anion-exchange HiTrap Q HP column. The protein was eluted by a salt gradient in buffer A (20 mM Tris-HCl pH = 8, 50 mM NaCl 10% glycerol and 3 mM  $\beta$ -ME). The purity of the protein was verified on SDS-PAGE in 15% acrylamide:bis-acrylamide gel, stained with Coomassie brilliant blue. The protein was concentrated to 2.8 mg/mol frozen in N<sub>2</sub>(l) and kept at -80 °C.

The gene encoding the PL<sup>pro</sup> (also known as nsp3) protein from SARS-CoV-2 (YP\_009725299.1) was also synthesized commercially (Invitrogen) and cloned into the pSUMO1 vector with N-terminal 8xHis conjugated with yeast SUMO, forming a fusion solubility/affinity tag. The plasmid was transformed into *E. coli* NiCo21 (DE3) and expressed in ZY5052 autoinduction media supplemented with 50  $\mu$ M ZnSO<sub>4</sub> and affinity purified identically as the NS2B-NS3<sup>pro</sup>. The protein was desalted on a HiPrep 26/10 desalting column (GE Healthcare) and loaded on an anion-exchange HiTrap Q HP column (GE Healthcare). Next, the 8xHis-SUMO-tag was cleaved using SUMO protease from yeast (Ulp1), and after overnight incubation at 4°C, the sample was loaded onto a HisTrap HP, equilibrated in a lysis buffer. Unbound fractions containing PL<sup>pro</sup> were pooled, concentrated and loaded on a Superdex 75 HiLoad 16/600 column (GE Healthcare) equilibrated with 20 mM Tris-HCl pH = 7,4; 50 mM NaCl; 10% glycerol and 3 mM  $\beta$ -ME. The protein was concentrated, frozen in N<sub>2</sub>(l) and kept at -80 °C.

### **Preparation of fluorescent substrates eGFP-RSSRRSDLVFS-mCherry and mCherry-ISG-15-eGFP**

A substrate for the proteolytic reaction of NS2B-NS3<sup>pro</sup> was designed to have a sequence (RSSRRSDLVFS) derived from a cleavage site present between the NS2B and NS3 of TBEV, flanked by GFP and mCherry fluorophores resulting in a plasmid encoding for GFP-RSSRRSDLVFS-mCherry. The plasmid was prepared by restriction cloning. First, a gene encoding for GFP was cloned in the pHis2 vector. In the second step, the NS2B-NS3<sup>pro</sup> site and mCherry were added. The plasmid was transformed into the *E. coli* NiCo21 (DE3), and the protein was expressed in LB medium supplemented with 0.1  $\mu$ g/ml of ampicillin, 10  $\mu$ M ZnSO<sub>4</sub>, 1 mM of MgCl<sub>2</sub> and MgSO<sub>4</sub>, 0.25 mM KCl, and 15  $\mu$ M FeCl<sub>2</sub> dissolved in citric acid. The media was incubated in a shaker at 37 °C. After reaching an OD<sub>600</sub> of 0.4, the temperature was lowered to 25 °C, at which 0.3  $\mu$ M IPTG was added to initiate the expression. The temperature was immediately lowered to 18 °C, and the culture was grown overnight. The purification steps were similar to those used to produce the NS2B-NS3<sup>pro</sup>. The cells were briefly lysed by sonication in a lysis buffer (20 mM Tris-HCl pH = 8; 300 mM NaCl; 20mM imidazole; 10% (v/v) glycerol and 3 mM  $\beta$ -ME), and then supplemented with one tablet/l of the complete mini EDTA-free protease inhibitor cocktail. The supernatant was purified in a Ni-NTA column, Superdex 75 HiLoad 16/600 column, HiPrep 26/10 desalting column, and HiTrap Q HP column, respectively, using the same

buffers and procedures as described above. Additionally, NaCl was added to a final concentration of 800 mM and the protein was further purified on the Superdex 75 HiLoad 16/600 column. The enzyme stored in -80 °C.

Human *ISG15* is the substrate of SARS-CoV-2 PL<sup>pro</sup>. The gene encoding ISG15 was subcloned in between genes encoding the FRET pair consisting of mCherry and eGFP (Figure 1A). All these components were amplified using PCR, and they were cloned into the plasmid pET-24a using a Gibson assembly [25]. The plasmid was transformed into *E. coli* NiCo21 (DE3), expressed and purified to homogeneity. The final recombinant protein used for the assays contained an N-terminal 6 x His-Tag, mCherry, a cleavage site for TEV protease, ISG15 and eGFP (mCherry-ISG15-eGFP). The TEV site was included for validation and versatility of the substrate.

### **FRET-based assays of the NS2B-NS3<sup>pro</sup> and PL<sup>pro</sup> activity and inhibition**

The reactions of the proteases and their FRET substrates were performed in 80 µl in black 384-well plates. In the case of NS2B-NS3<sup>pro</sup> reactions, there was a 2.5 µM protease and 0.25 µM substrate. In the case of the PL<sup>pro</sup> reaction, there was 20 nM protease and 1 µM substrate. The reaction buffer contained 20 mM Tris-HCl pH = 7, 10 mM NaCl, 3 mM β-ME for NS2B-NS3<sup>pro</sup> or 20 mM Tris-HCl pH = 7.4, 50 mM NaCl, 10 % Glycerol, 3 mM β-ME for PL<sup>pro</sup>. The reaction conditions were optimized to fulfil the HTS character. In the case of the inhibitor 5,5-dithio-bis-(2-nitrobenzoic acid) (DTNB), β-ME was omitted from the buffer due to the easy reduction of DTNB to 2-nitro-5-thiobenzoate (TNB). Similarly, β-ME was omitted in the cases of 2-MP, 6-MP and Antabuse. The enzyme stock solution was desalted using the MicroSpin G-25 columns (Cytiva) when testing the easily reduced inhibitors. The titration series of the inhibitor was performed in a mixture containing a constant concentration of the substrate. Reactions were initiated by mixing equal volumes (i.e. 40 µl) of the mixture containing the substrate and inhibitor with a mixture containing the enzyme. For the negative control, the substrate mixture did not include the inhibitor. Another control was set up by not adding the enzyme into the reaction mixture. Every reaction was performed in triplicate. Measurements were performed using the Tecan microplate reader at 25 °C for 6 hours (NS2B-NS3<sup>pro</sup>) or 40-60 mins (PL<sup>pro</sup>). To prevent the NS2B-NS3<sup>pro</sup> reaction mixture from evaporating, the plates were covered with a transparent Crystal Clear Sealing tape (Hampton research).

In the reaction, the decreasing fluorescence (FRET) intensity of mCherry was monitored at an emission wavelength of 610 nm. The excitation wavelength was 488 nm, with a 5 nm bandwidth for both slits. The lag time was zero, the integration time was 20 µs, and the settle time was 10 ms for 400 Hz of flash frequency. An optimal 96% gain was calculated in every measurement. A Z-position was set at 20000 µm height. For each time point, 10 flashes were integrated and combined with the multiple reads per well with 100 µm offset from the border of the well. At the end of the measurement, SDS sample buffer

(20 mM Tris-HCl, pH = 8.8; 0,25 M glycine; 0,1% (w/w) SDS) was added to terminate the reaction and validate the progress on the SDS-PAGE. The gel was scanned, using a laser at 532 nm and filter at 660 nm on the Amersham Typhoon Biomolecular Imager (Cytiva).

### **Determination of the inhibitor potency**

To quantify the inhibitory effect of the tested molecules, we determined the half maximal inhibitory concentration ( $IC_{50}$ ) from the measured data. The slope of relative fluorescence units (RFU) versus time was calculated from points in the first 2.5 hours in the case of NS2B-NS3<sup>pro</sup>, and 40-60 min in the case of PL<sup>pro</sup>. As the slope corresponded to the reaction velocity, we normalized every calculated slope of the inhibition reaction according to the calculated slope of the two control reactions—one in which the inhibitor was omitted (100% activity), and the second in which both inhibitor and enzyme were omitted (0% activity). These normalized data were plotted against the log of the concentration of the inhibitor to give an  $IC_{50}$  curve of the specific inhibitor.

## **Results**

### **Preparation of TBEV chymotrypsin-like protease and SARS-CoV2 papain-like protease**

The proteolytic activity of the TBEV NS3 protease is dependent on association with the NS2B cofactor. We prepared the NS2B-NS3 protease construct composed of NS2B (residues 45-96 linked with residues 116 to 131), followed by residues 1-190 of NS3 linked via a glycine-rich linker (Figure S1A). This construct is similar to the constructs previously used to express other active and soluble flaviviral proteases, such as DENV [26]. The recombinant NS2B-NS3<sup>pro</sup> protease was transformed and expressed in *E. coli* NiCo21 (DE3) cells and purified to homogeneity with yields of 2.4 mg per 1 litre of *E. coli* culture. The junction between NS2B and NS3 was cleaved by autoproteolytic activity during the purification (Figure S1B) as it has been observed for ZIKV protease [18]. The cleavage site corresponds to the enzyme's specificity for two basic residues followed by a small residue (here Arg-Arg-Ser) which directly confirmed the *in vitro* enzymatic activity. PL<sup>pro</sup> from SARS-CoV2 was recently recognized to facilitate specific cleavage of the di-ubiquitin-like protein ISG15 [27]. We have also produced the PL<sup>pro</sup> protein recombinantly in *E. coli* and purified it to homogeneity

### **Fluorogenic substrates for NS2B-NS3<sup>pro</sup> and PL<sup>pro</sup> and optimization of activity assays**

A sequence of the substrate for the proteolytic reaction of NS2B-NS3<sup>pro</sup> was designed to have a natural cleavage site present between the NS2B and NS3 of TBEV, flanked by GFP and mCherry fluorescent proteins on the N and C terminus, respectively (Figure 1). This recombinant substrate was expressed in *E. coli* and purified to homogeneity. The fluorogenic PL<sup>pro</sup> substrate was generated similarly as for

NS2B-NS3<sup>pro</sup>, but the substrate molecule, ISG15, was cloned between the genes for the identical FRET pair (mCherry and eGFP) (Figure 1). This fusion protein was recombinantly expressed in *E. coli* and purified to homogeneity too.

The activities of both NS2B-NS3<sup>pro</sup> and PL<sup>pro</sup> were tested *in vitro* using small-batch reactions in physiological conditions. The results of these reactions and the subsequent activity of both proteases were validated on an SDS-PAGE based assay (Figure 1). Then, the fluorescent properties of NS2B-NS3<sup>pro</sup> and PL<sup>pro</sup> substrates were tested on a plate reader with adjustable wavelength (Tecan). In the case of FRET-based kinetics, both the increase of the donor fluorescence or decrease of the acceptor fluorescence can be followed to determine the rate of the reactions. We measured both the excitation and the emission spectra of the substrate and of the final product. This allowed us to determine the spectral conditions where the change of fluorescence was greatest upon the addition of the enzyme (Figure S2). The optimal excitation wavelength was 488 nm and the optimal emission wavelength was 610 nm. These parameters were used for all the FRET measurements.

### **Quantitative FRET assay for testing potential inhibitors of viral proteases in a high-throughput format**

With established reaction conditions for the assay, we proceeded to measure the optimal enzyme concentration to achieve steady-state kinetics where the reaction rate is constant. This allows the linear fit of reaction rates for a given well. It additionally gives sufficient time for the measurement of the reactions in a high-throughput mode in the entire plate. We tested serial dilutions of enzymes with constant amounts of the substrate. The fluorescence change and reaction rates were satisfactory when we used 1  $\mu$ M substrate and 20 nM enzyme in the case for PL<sup>pro</sup>, and 0.25  $\mu$ M substrate and 2.5  $\mu$ M enzyme in the case for NS2B-NS3<sup>pro</sup> (Figure 1-3).

We selected several inhibitors of PL<sup>pro</sup> and NS2B-NS3<sup>pro</sup> to be tested in our FRET-based assay in the 384-well plate format. All inhibitors were dissolved close to their solubility limits to achieve the maximum range of concentrations in individual assays. Typically, we prepared inhibitors at 3 mM, 10 mM or 50 mM concentrations and, where possible, serial dilutions of inhibitors in the reaction buffer were used. The 384-well plate layout of the reaction allowed for the following setup: two control reactions where no enzyme or inhibitor was present, twelve to sixteen different reactions with a gradient of concentration, and one control with both enzyme and substrate. In this set, the reactions were measured in three to four technical replicates, and all of the sets of these reactions were repeated at least three times. The time allowed for the proteolytic reaction was 40-60 mins for PL<sup>pro</sup>, and 6 hours for NS2B-NS3<sup>pro</sup>. Our intention was the rapid measurement of the IC<sub>50</sub> values in a broad range of concentrations. Up to 3 different inhibitors were measured simultaneously. The assay setup was

optimized such that the linear phase of the reaction would be sufficiently long to allow the mixing and measuring of the entire plate of 384-wells.

### **FRET-based high-throughput assay determines reproducible IC<sub>50</sub> values**

Fluorogenic substrates with protease-specific cleavage sites were used to investigate the activity of the PL<sup>pro</sup> and NS2B-NS3<sup>pro</sup> and their inhibition by small molecule and peptide inhibitors. To quantitatively measure the potency of the potential inhibitors, we determined their IC<sub>50</sub> values. The optimum concentration of enzymes and their substrates were used for all the inhibition reactions, i.e. 20 nM enzyme and 1 μM substrate, and 2.5 μM enzyme and 0.25 μM substrate were used for PL<sup>pro</sup> and NS2B-NS3<sup>pro</sup>, respectively. The radical excess of NS2B-NS3<sup>pro</sup> over its substrate was used to compensate for the low activity of this protease *in vitro*. At a 1:1 molar ratio between the enzyme and its substrate, the reaction went to completion in 16 hours. Upon the 10-fold saturation with the enzyme, the reaction time was effectively reduced to 6 hours.

### **The potency of TBEV NS2B-NS3<sup>pro</sup> inhibitors**

TBEV protease has not been characterized structurally. However, it is known that the flaviviral NS2B-NS3<sup>pro</sup> is a serine protease that is highly conserved among the Flavivirus genus [22]. Therefore, we have chosen to test several commercially available inhibitors that are sufficiently soluble and their interaction with the ZIKV, DENV and WNV proteases was well characterized (DTNB, aprotinin) [17, 18, 28]. Additionally, leupeptin was picked to represent a broad-spectrum protease inhibitor [29].

The measured IC<sub>50</sub> values are listed in SI Table 1. Figure 2 shows the dose-response curves and illustrative SDS-PAGE gels. In the case of leupeptin, there was no inhibition observed as confirmed by the SDS-PAGE analysis. Aprotinin (also known as bovine pancreatic inhibitor), a competitive serine protease inhibitor, inhibits the TBEV protease with an IC<sub>50</sub> value of  $2.4 \pm 0.2$  μM. DTNB, an allosteric inhibitor, inhibited the enzyme with an IC<sub>50</sub> value of  $303 \pm 54$  μM. The DTNB molecule inhibits enzymes by forming disulfide bonds with cysteine residues on their surface. Therefore, reducing agents needed to be omitted from the reaction buffer and the enzyme stock solution (containing β-ME) was desalted to avoid premature reduction of DTNB. As expected, desalting resulted in increased instability of the enzyme and a tendency to precipitate. Rapid manipulation at low temperature was thus essential prior to the measurement.

## Potential SARS-CoV-2 PL<sup>pro</sup> inhibitors, Antabuse inhibits PL<sup>pro</sup> within the nanomolar range

For the establishment and validity of the high-throughput character of our assay, we have selected 2-mercaptapurine (2-MP), 6-mercaptapurine (6-MP), JB24, Antabuse and aprotinin (SI Figure 3), and tested them with the PL<sup>pro</sup> enzyme.

All the reactions were tested in the same aforementioned conditions. As expected, aprotinin displayed no inhibition of the enzyme in the measured range of concentrations. We synthesized JB24 as previously described as compound number 24 [30]. This molecule inhibited PL<sup>pro</sup> significantly with an IC<sub>50</sub> of 1.48 ± 0.39 μM. These two small molecules were utilized during the optimization of the assay. The results were reproducible as individual titrations were measured with different batches of defrosted and newly diluted enzyme and a substrate (Figure 3).

Next, Antabuse, 2-MP and 6-MP were tested in order to measure their inhibition properties on PL<sup>pro</sup>. The inhibition of these compounds is sensitive to reducing agents. Therefore, the reducing agent had to be omitted from the reactions. It is noteworthy that even in the presence of a reducing agent only in the stock solution of substrate and enzyme, it influenced the IC<sub>50</sub> values of these compounds [31]. Therefore, it had to be removed from the reaction by desalting. Antabuse inhibition was 80 ± 38 nM in the absence of DTT or β-ME. Interestingly, only 2-MP but not 6-MP had an inhibitory effect on PL<sup>pro</sup> (IC<sub>50</sub> = 0.82 ± 0.6 μM). 2-MP inhibition was also diminished by the presence of DTT in the reaction buffer.

## Discussion

The assay presented in this study offers a rapid, inexpensive and sensitive high-throughput screening of protease inhibitors. We demonstrate its effectivity and robustness on two viral proteases which differ both in specificity and activity. Both proteases represent significant therapeutic targets. The protease from SARS-CoV-2, a papain-like protease (PL<sup>pro</sup>), is a relatively fast acting enzyme which prevents cellular antiviral response by its DUB activity. The second protease, formed by the nonstructural proteins 2B and 3 (NS2B-NS3<sup>pro</sup>), from the tick-borne encephalitis virus (TBEV) processes newly synthesized TBEV polyprotein during viral infection and displays low catalytic activity *in vitro*.

To validate the assay quantitatively, we obtained reproducible values of the half maximal inhibitory concentration (IC<sub>50</sub>). Aprotinin (also known as the bovine pancreatic inhibitor) inhibited NS2B-NS3<sup>pro</sup> with an IC<sub>50</sub> of 2.35 μM at an enzyme concentration of 2.5 μM. Notably, this protease is inhibited significantly less efficiently than other proteases of Flaviviruses. For instance, the WNF protease displayed an IC<sub>50</sub> of 20 nM when the enzyme concentration was 10 nM [32], and the DENV protease displayed an IC<sub>50</sub> of 65 nM when the enzyme concentration was 1 μM [33].

We have demonstrated the versatility of this assay and that the fluorogenic substrate can be prepared easily by recombinant expression in *E. coli*. Moreover, the recombinant character of the substrate broadens the area for the assessment to practically any protease from any source from viruses to humans. In the case of our assay, eGFP and mCherry have been used for several reasons. The genes of these molecules are readily available in most laboratories. The excitation maximum of eGFP is in the vicinity of one of the most commonly used lasers (argon laser, 488 nm), which is available on most instruments. Our assays with enzymes from very distinct kinetics have demonstrated the practicality of our choice of the FRET pair (eGFP and mCherry) in combination within the gel-based assays. Both eGFP and mCherry are very stable proteins with sufficiently good FRET efficiency for the assay. In the case of further revalidation in the PAGE gel, the larger spectral differences are advantageous. Importantly, for enhanced sensitivity of this type of assay, other FRET pairs such as the CyPet-YPet pair could be considered. This pair offers greater FRET emission gains, especially when instrumental setup allows for excitation at 414 nm and the collection of emissions at 530 nm [34].

In comparison with radioisotope-based methods, the fluorescence-based methods are safe to use, easy to operate, and the measurements and possible evaluation are carried out in real-time. In most cases, our fluorescent assay does not require further manipulation and analysis of the sample, e.g. separation of reactants from products and measurements. On the other hand, interference from other components of the assay may be an issue in case of fluorescent assays and has to be taken into consideration. These components may interfere with the assay by altering the amount of fluorescent signal and decreasing the sensitivity of the assay. In the proper set-up of our assay, the photobleaching of the components can be corrected for by running the controls for the assay, e.g. fluorescent substrate without the enzyme. It is noteworthy that the fluorescent substrate, cofactors or inhibitors may interfere with the assay in such a way that FRET-based results are not suitable for evaluation. In such a case, assays can be resolved on a PAGE gel, with the cost of a lower throughput.

Other fluorescent techniques besides FRET-based methods may be considered to be applicable for measurements of the rate of proteolysis, especially in similar sample setups where the large fluorescent substrate is proteolytically cleaved to one or several small fluorescent molecules. In this case, fluorescence anisotropy or polarisation (FA/FP), homogeneous time-resolved fluorescence (HTRF), and fluorescence correlation spectroscopy (FCS) are among these options. There are advantages and disadvantages to all of these methods, however, there is one key aspect that outweighs these excellent techniques in favour of FRET-based techniques and that is its suitability for the HTS.


The recent advances in FCS allow measurements in high-throughput mode, but the instrument cost, complex evaluation and speed in processing of the samples may be a major obstacle in the use of such a method [35]. On the other hand, when the number of available components is limited and there are low volumes of the sample, confocal microscopy may be favorable. Although FP and HTRF methods

can be also used in high-throughput screening (HTS), they require more complex instrumentation and evaluation of the results. In this case, low cost and greater versatility, modality and possibly greater sensitivity favour the FRET-based method [36].

The other fluorescent-based methods have plenty of advantages, but one of the overwhelming factors in favour of this assay is its low cost and versatility of preparation. This assay can be easily performed in a typical laboratory and only requires a fluorescent plate reader. The fluorescent parameters of the substrate may be tailored to suit the available instruments of a particular researcher and to the given application, e.g. mutagenic study of the variability of the substrate or testing the enzyme kinetics. Since the substrate is recombinant, it avoids costly synthesis of specific substrates with synthetic fluorescent probes that might be essential for the aforementioned methods.


Fluorescence assays typically offer the best balance between cost and sensitivity in high-throughput screening (HTS) experiments.

Rapid response to threats posed by viral pathogens is and will clearly continue to be one of the most important challenges for our globalized society. This response is associated with our ability to quickly design and prepare new antivirals that will be able to affect these pathogens at their weakest points. Experience with the discovery of drugs against both HIV and HCV illustrates that viral proteases are important drug targets. Here, we have shown that it is possible to quickly and efficiently develop an assay against various viral proteases and convert it to the HTS format. Therefore, the assay developed here is a very useful tool for early drug discovery and can be quickly designed and used for both drug repurposing and the identification of completely new protease inhibitors in fight against various viral pathogens.




**Figure 1: Substrates, principles of FRET assay and its optimization**

(A) The fluorescent PL<sup>pro</sup> and NS2B-NS3<sup>pro</sup> substrates (B) schematics of the FRET-based proteolytic assay, eGFP is excited with a green light at 488 nm, FRET transfers the excitation to mCherry which emits the light that is detected. After proteolytic cleavage, this FRET signal is abolished, (C-D) the reaction of PL<sup>pro</sup> substrate with a serial dilution of PL<sup>pro</sup> enzyme (500nM - 10 nM) (C) raw data of reactions followed in the fluorescent plate reader (D) these reactions were loaded on SDS PAGE gel and visualized on a fluorescent scanner.



**Figure 2: Inhibition effects of TBEV NS2B-NS3pro by small molecules.**

Curves derived from the FRET inhibition assays of (A) aprotinin, (C) DTNB, and (D) leupeptin. (B) Validation by SDS-PAGE analysis showing the successful inhibition by aprotinin (top) and no inhibition by leupeptin (bottom) where (M) is a marker, (S<sub>F</sub>) is fresh substrate at reaction concentration, (+) is positive control reaction where there was no inhibitor present, (-) is negative control reaction where there was no enzyme present, (S) is the substrate, (P) is the product.



**Figure 3: Inhibition effects of SARS-CoV2 PL<sup>pro</sup> by small molecules;**

Curves derived from the FRET inhibition assays of (A) JB24, (C) Antabuse, and (D) 2-MP and 6-MP. (B) SDS PAGE gel from one of the titrations with JB24 where (M) is a marker, (+) is a positive control reaction where there was no inhibitor present, (-) is a negative control reaction where there was no enzyme preset, (S) is the substrate, and (P) is the product.

## Acknowledgements

The work was supported by the European Regional Development Fund; OP RDE; Project: "Chemical biology for drugging undruggable targets (ChemBioDrug)" (No. CZ.02.1.01/0.0/0.0/16\_019/0000729). The Academy of Sciences of the Czech Republic (RVO: 61388963) is also acknowledged. We are grateful to Tamara Jenkins for critical reading of the manuscript.

## Author Contributions

BC, AH, JB, and JS performed experiments. EB designed the study, RN, EB and JS supervised the study. BC, EB and JS wrote the manuscript.

## Conflicts of Interest

The authors declare no conflict of interest.

## References

1. Woolhouse, M.E.J. and L. Brierley, *Epidemiological characteristics of human-infective RNA viruses*. *Sci Data*, 2018. **5**: p. 180017.
2. Wolf, Y.I., D. Kazlauskas, J. Iranzo, A. Lucia-Sanz, J.H. Kuhn, M. Krupovic, V.V. Dolja, and E.V. Koonin, *Origins and Evolution of the Global RNA Virome*. *mBio*, 2018. **9**(6).
3. Domingo, E. and J.J. Holland, *RNA virus mutations and fitness for survival*. *Annu Rev Microbiol*, 1997. **51**: p. 151-78.
4. Bentley, K. and D.J. Evans, *Mechanisms and consequences of positive-strand RNA virus recombination*. *J Gen Virol*, 2018. **99**(10): p. 1345-1356.
5. Rosenberg, R., *Detecting the emergence of novel, zoonotic viruses pathogenic to humans*. *Cell Mol Life Sci*, 2015. **72**(6): p. 1115-25.
6. Holmes, E.C., *The evolutionary genetics of emerging viruses*. *Annu. Rev. Ecol. Evol. Syst.*, 2009. **40**: p. 353-372.
7. De Clercq, E., *Strategies in the design of antiviral drugs*. *Nat Rev Drug Discov*, 2002. **1**(1): p. 13-25.
8. Dzimianski, J.V., F.E.M. Scholte, E. Bergeron, and S.D. Pegan, *ISG15: It's Complicated*. *J Mol Biol*, 2019. **431**(21): p. 4203-4216.
9. Perng, Y.C. and D.J. Lenschow, *ISG15 in antiviral immunity and beyond*. *Nat Rev Microbiol*, 2018. **16**(7): p. 423-439.
10. Devaraj, S.G., N. Wang, Z. Chen, Z. Chen, M. Tseng, N. Barretto, R. Lin, C.J. Peters, C.T. Tseng, S.C. Baker, and K. Li, *Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus*. *J Biol Chem*, 2007. **282**(44): p. 32208-21.

11. Bailey-Elkin, B.A., R.C. Knaap, G.G. Johnson, T.J. Dalebout, D.K. Ninaber, P.B. van Kasteren, P.J. Bredenbeek, E.J. Snijder, M. Kikkert, and B.L. Mark, *Crystal structure of the Middle East respiratory syndrome coronavirus (MERS-CoV) papain-like protease bound to ubiquitin facilitates targeted disruption of deubiquitinating activity to demonstrate its role in innate immune suppression*. J Biol Chem, 2014. **289**(50): p. 34667-82.
12. Ratia, K., S. Pegan, J. Takayama, K. Sleeman, M. Coughlin, S. Baliji, R. Chaudhuri, W. Fu, B.S. Prabhakar, M.E. Johnson, S.C. Baker, A.K. Ghosh, and A.D. Mesecar, *A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication*. Proc Natl Acad Sci U S A, 2008. **105**(42): p. 16119-24.
13. Ruzek, D., T. Avsic Zupanc, J. Borde, A. Chrdle, L. Eyer, G. Karganova, I. Kholodilov, N. Knap, L. Kozlovskaya, A. Matveev, A.D. Miller, D.I. Osolodkin, A.K. Overby, N. Tikunova, S. Tkachev, and J. Zajkowska, *Tick-borne encephalitis in Europe and Russia: Review of pathogenesis, clinical features, therapy, and vaccines*. Antiviral Res, 2019. **164**: p. 23-51.
14. Piesman, J. and L. Eisen, *Prevention of tick-borne diseases*. Annu Rev Entomol, 2008. **53**: p. 323-43.
15. Pfeffer, M. and G. Dobler, *Emergence of zoonotic arboviruses by animal trade and migration*. Parasit Vectors, 2010. **3**(1): p. 35.
16. Dubankova, A. and E. Boura, *Structure of the yellow fever NS5 protein reveals conserved drug targets shared among flaviviruses*. Antiviral Res, 2019. **169**: p. 104536.
17. Erbel, P., N. Schiering, A. D'Arcy, M. Renatus, M. Kroemer, S.P. Lim, Z. Yin, T.H. Keller, S.G. Vasudevan, and U. Hommel, *Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus*. Nat Struct Mol Biol, 2006. **13**(4): p. 372-3.
18. Phoo, W.W., Y. Li, Z. Zhang, M.Y. Lee, Y.R. Loh, Y.B. Tan, E.Y. Ng, J. Lescar, C. Kang, and D. Luo, *Structure of the NS2B-NS3 protease from Zika virus after self-cleavage*. Nat Commun, 2016. **7**: p. 13410.
19. Hercik, K., J. Brynda, R. Nencka, and E. Boura, *Structural basis of Zika virus methyltransferase inhibition by sinefungin*. Arch Virol, 2017. **162**(7): p. 2091-2096.
20. Hercik, K., J. Kozak, M. Sala, M. Dejmek, H. Hrebabecky, E. Zbornikova, M. Smola, D. Ruzek, R. Nencka, and E. Boura, *Adenosine triphosphate analogs can efficiently inhibit the Zika virus RNA-dependent RNA polymerase*. Antiviral Res, 2017. **137**: p. 131-133.
21. Konkolova, E., M. Dejmek, H. Hrebabecky, M. Sala, J. Boserle, R. Nencka, and E. Boura, *Remdesivir triphosphate can efficiently inhibit the RNA-dependent RNA polymerase from various flaviviruses*. Antiviral Res, 2020. **182**: p. 104899.
22. da Fonseca, N.J., Jr., M.Q. Lima Afonso, N.G. Pedersolli, L.C. de Oliveira, D.S. Andrade, and L. Bleicher, *Sequence, structure and function relationships in flaviviruses as assessed by evolutive aspects of its conserved non-structural protein domains*. Biochem Biophys Res Commun, 2017. **492**(4): p. 565-571.

23. Chambers, T.J., R.C. Weir, A. Grakoui, D.W. McCourt, J.F. Bazan, R.J. Fletterick, and C.M. Rice, *Evidence that the N-terminal domain of nonstructural protein NS3 from yellow fever virus is a serine protease responsible for site-specific cleavages in the viral polyprotein*. Proc Natl Acad Sci U S A, 1990. **87**(22): p. 8898-902.
24. Lakowicz, J.R., *Principles of fluorescence spectroscopy*. 3rd ed. 2006, New York: Springer. xxvi, 954 p.
25. Gibson, D.G., L. Young, R.Y. Chuang, J.C. Venter, C.A. Hutchison, 3rd, and H.O. Smith, *Enzymatic assembly of DNA molecules up to several hundred kilobases*. Nat Methods, 2009. **6**(5): p. 343-5.
26. Shannon, A.E., M.M. Pedroso, K.J. Chappell, D. Watterson, S. Liebscher, W.M. Kok, D.P. Fairlie, G. Schenk, and P.R. Young, *Product release is rate-limiting for catalytic processing by the Dengue virus protease*. Sci Rep, 2016. **6**: p. 37539.
27. Shin, D., R. Mukherjee, D. Grewe, D. Bojkova, K. Baek, A. Bhattacharya, L. Schulz, M. Widera, A.R. Mehdipour, G. Tascher, P.P. Geurink, A. Wilhelm, G.J. van der Heden van Noort, H. Ovaa, S. Muller, K.P. Knobloch, K. Rajalingam, B.A. Schulman, J. Cinatl, G. Hummer, S. Ciesek, and I. Dikic, *Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity*. Nature, 2020.
28. Voss, S. and C. Nitsche, *Inhibitors of the Zika virus protease NS2B-NS3*. Bioorg Med Chem Lett, 2020. **30**(5): p. 126965.
29. Billinger, E., J. Viljanen, S. Bergstrom Lind, and G. Johansson, *Inhibition properties of free and conjugated leupeptin analogues*. FEBS Open Bio, 2020.
30. Ghosh, A.K., J. Takayama, Y. Aubin, K. Ratia, R. Chaudhuri, Y. Baez, K. Sleeman, M. Coughlin, D.B. Nichols, D.C. Mulhearn, B.S. Prabhakar, S.C. Baker, M.E. Johnson, and A.D. Mesecar, *Structure-based design, synthesis, and biological evaluation of a series of novel and reversible inhibitors for the severe acute respiratory syndrome-coronavirus papain-like protease*. J Med Chem, 2009. **52**(16): p. 5228-40.
31. Lin, M.H., D.C. Moses, C.H. Hsieh, S.C. Cheng, Y.H. Chen, C.Y. Sun, and C.Y. Chou, *Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes*. Antiviral Res, 2018. **150**: p. 155-163.
32. Shiryaev, S.A., B.I. Ratnikov, A.V. Chekanov, S. Sikora, D.V. Rozanov, A. Godzik, J. Wang, J.W. Smith, Z. Huang, I. Lindberg, M.A. Samuel, M.S. Diamond, and A.Y. Strongin, *Cleavage targets and the D-arginine-based inhibitors of the West Nile virus NS3 processing proteinase*. Biochem J, 2006. **393**(Pt 2): p. 503-11.
33. Leung, D., K. Schroder, H. White, N.X. Fang, M.J. Stoermer, G. Abbenante, J.L. Martin, P.R. Young, and D.P. Fairlie, *Activity of recombinant dengue 2 virus NS3 protease in the presence of a truncated NS2B co-factor, small peptide substrates, and inhibitors*. J Biol Chem, 2001. **276**(49): p. 45762-71.
34. Liu, Y., Y. Song, V. Madahar, and J. Liao, *Quantitative Forster resonance energy transfer analysis for kinetic determinations of SUMO-specific protease*. Anal Biochem, 2012. **422**(1): p. 14-21.
35. Nakata, H., T. Ohtsuki, and M. Sisido, *A protease inhibitor discovery method using fluorescence correlation spectroscopy with position-specific labeled protein substrates*. Anal Biochem, 2009. **390**(2): p. 121-5.

36. Degorce, F., A. Card, S. Soh, E. Trinquet, G.P. Knapik, and B. Xie, *HTRF: A technology tailored for drug discovery - a review of theoretical aspects and recent applications*. Curr Chem Genomics, 2009. **3**: p. 22-32.